Gout - canakinumab [ID461]

Canakinumab for the treatment of gouty arthritis attacks and reduction in frequency of subsequent attacks

Status: History
Expected date of issue: TBC
Referral date: May 2011
Process: STA

Scoped within Batch 17

Topic area:
  • Musculoskeletal

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Richard Diaz
Communications manager: Tonya Gillis
Project manager: Rebecca Pye


Provisional schedule

Closing date for invited submissions / evidence submission: 15 March 2012
1st appraisal committee meeting: TBC


Consultees and commentators



Commentators (no right to submit or appeal)



  • Novartis (canakinumab)

Patient/carer groups

  • Action on Pain
  • Afiya Trust
  • Arthritic Association
  • Arthritis and Musculoskeletal Alliance (ARMA)
  • Arthritis Care
  • Black Health Agency
  • British Kidney Patient Association
  • Counsel and Care
  • Equalities National Council
  • Kidney Alliance
  • Kidney Research UK
  • Muslim Council of Britain
  • Muslim Health Network
  • National Kidney Federation
  • National Rheumatoid Arthritis Society
  • Pain Concern
  • Pain Relief Foundation
  • South Asian Health Foundation
  • Specialised Healthcare Alliance
  • UK Gout Society

Professional groups

  • Association of Renal Industries
  • Association of Renal Technologists
  • Bone Research Society
  • British Association for Services to the Elderly
  • British Dietetic Association
  • British Geriatrics Society
  • British Health Professionals in Rheumatology
  • British Institute of Musculoskeletal Medicine
  • British Orthopaedic Association
  • British Pain Society
  • British Renal Society
  • British Society for Rheumatology
  • British Society of Rehabilitation Medicine
  • Chartered Society of Physiotherapy
  • College of Occupational Therapists
  • National Pharmacy Association
  • Physiotherapy Pain Association
  • Primary Care Rheumatology Society
  • Renal Association
  • Rheumatoid Arthritis Surgical Society
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal Pharmaceutical Society
  • Royal Society of Medicine
  • Society for DGH Nephrologists
  • Society for Endocrinology
  • United Kingdom Clinical Pharmacy Association


  • Department of Health
  • NHS Eastern and Coastal Kent
  • NHS Northamptonshire
  • Welsh Government


  • Board of Community Health Councils in Wales
  • British National Formulary
  • Care Quality Commission
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency
  • National Association of Primary Care
  • NHS Alliance
  • NHS Commercial Medicines Unit
  • NHS Confederation
  • Public Health Wales NHS Trust
  • Scottish Medicines Consortium
  • Welsh Kidney Patients Association

Comparator manufacturer(s)

  • Actavis (prednisolone)
  • Alcon Laboratories (dexamethasone)
  • Allergan (dexamethasone, prednisolone)
  • Alliance pharmaceuticals (prednisolone)
  • Amdipharm (hydrocortisone, prednisolone)
  • Bausch & Lomb UK (dexamethasone, prednisolone)
  • Boots company (hydrocortisone)
  • E.R.Squibb & Sons (triamcinolone)
  • Forest Laboratories (prednisolone)
  • Hospira UK (dexamethasone)
  • Meda pharmaceuticals (hydrocortisone)
  • Merck, Sharp and Dohme (dexamethasone)
  • Pfizer (methylprednisolone)
  • Rosemont Pharmaceuticals (dexamethasone)
  • Sanofi (cortisone acetate, deflazacort)
  • Winthrop Pharmaceuticals (prednisolone)
  • Wockhardt UK (prednisolone)

Relevant research groups

  • Arthritis Research UK
  • Chronic Pain Policy Coalition
  • Cochrane Musculoskeletal Group
  • MRC Clinical Trials Unit
  • National Institute for Health Research
  • Research Institute for the Care of Older People

Evidence Review Group

  • Warwick Evidence
  • National Institute for Health Research Health Technology Assessment Programme

Associated public health groups

  • None

Associated guideline groups

  • National Clinical Guidelines Centre



Project history

Date Update
27 January 2012

The manufacturer of canakinumab has informed NICE that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal.

17 August 2011

As you are aware, the Department of Health has asked us to carry out a single technology appraisal of canakinumab for the treatment of gouty arthritis attacks as part of our 26th wave work programme.  

Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin during mid January 2012 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid  March 2012.



Key documents

This page was last updated: 19 April 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.